Saturday, June 28, 2025 6/28/2025

Non-viral gene therapy with eCD4-Ig

Award Number: R56AI189343
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/17/2025
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

Non-viral gene therapy with eCD4-Ig - ABSTRACT We are developing non-viral gene therapy with eCD4-Ig as a practical approach for suppressing HIV replication for a lifetime after a one-time intramuscular injection. The error-prone nature of reverse transcriptase, and the sequence plasticity of the HIV envelope glycoprotein (Env), result in the rapid escape of neutralizing antibodies and daunting levels of global antigenic diversity. The antigenic diversity of HIV and ease of escape of antibody responses can be countered with eCD4-Ig, which is an antibody-like therapeutic protein constructed from parts of HIV’s primary receptor (CD4) and coreceptor (CCR5). eCD4-Ig functions like a broadly-neutralizing antibody (bNAb) in being able to neutralize virus infection and mediate effector functions, but cannot be escaped without HIV sacrificing its ability to bind its receptor and coreceptor. Here, we propose developing a non-viral gene therapy platform and its use to sustain therapeutically-effective plasma concentrations of eCD4-Ig for potentially a lifetime after a single administration. We propose basic science experiments that will inform the development of this non-viral gene therapy platform, plus the development of approaches for enhancing the efficiency of gene transfer into skeletal muscle. The proposed studies build on our work with adeno-associated virus (AAV) vectors to establish a state of long-term viral remission where further treatment is not required to suppress plasma viral loads to levels that are undetectable using standard assays. We and others term such a state of long-term viral suppression, albeit one short of eradication, a ‘functional cure.’ The lifelong expression of therapeutic concentrations of eCD4- Ig after a one-time intramuscular administration of a non-viral gene therapy vector is a feasible means of achieving a functional cure for HIV.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $919,501 )
2025	2025	EMMUNE INC	620 MEMORIAL DR STE W-100	CAMBRIDGE	MA	02139	MIDDLESEX	USA	Allergy and Infectious Diseases Research	000	1	6/17/2025	NEW	$919,501
														Subtotal = $919,501

Grand Total All Awards = $919,501

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Non-viral gene therapy with eCD4-Ig

Award Number: R56AI189343

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/17/2025

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer